WallStSmart

Abbott Laboratories (ABT)vsCarnival Corporation (CCL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 67% more annual revenue ($45.13B vs $26.98B). ABT leads profitability with a 13.9% profit margin vs 11.5%. CCL appears more attractively valued with a PEG of 1.09. CCL earns a higher WallStSmart Score of 70/100 (B).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

CCL

Strong Buy

70

out of 100

Grade: B

Growth: 8.7Profit: 7.0Value: 8.7Quality: 3.0
Piotroski: 5/9Altman Z: 0.89
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued
CCLUndervalued (+30.7%)

Margin of Safety

+30.7%

Fair Value

$47.73

Current Price

$26.38

$21.35 discount

UndervaluedFair: $47.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

CCL4 strengths · Avg: 8.8/10
P/E RatioValuation
11.9x10/10

Attractively priced relative to earnings

Return on EquityProfitability
27.9%9/10

Every $100 of equity generates 28 in profit

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
35.8%8/10

Earnings expanding 35.8% YoY

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

CCL2 concerns · Avg: 1.5/10
Altman Z-ScoreHealth
0.892/10

Distress zone — elevated risk

Debt/EquityHealth
2.281/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : CCL

The strongest argument for CCL centers on P/E Ratio, Return on Equity, Price/Book. PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : CCL

The primary concerns for CCL are Altman Z-Score, Debt/Equity. Debt-to-equity of 2.28 is elevated, increasing financial risk.

Key Dynamics to Monitor

CCL carries more volatility with a beta of 2.33 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CCL scores higher overall (70/100 vs 56/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Carnival Corporation

CONSUMER CYCLICAL · TRAVEL SERVICES · USA

Carnival Corporation & plc is a British-American cruise operator, currently the world's largest travel leisure company, with a combined fleet of over 100 vessels across 10 cruise line brands.

Visit Website →

Want to dig deeper into these stocks?